Share this article
Health Canada Approval Enables Quick and Accurate Blood Testing
TORONTO, April 27, 2021 /CNW/ - AA Pharma, a Canadian company focused on legacy pharmaceutical products, has secured the exclusive Canadian rights for the use of a blood analyzer for patients prescribed Clozapine. This medication, indicated for patients with Treatment Resistant Schizophrenia, requires regular blood monitoring.
Sight Diagnostics
Ⓡ received Health Canada approval for its Sight OLO
Ⓡ analyzer, which performs Complete Blood Count (CBC) tests, the most commonly ordered blood test because it offers insight into the status of a patient s overall health. The analyzer leverages a patented method of digitizing blood samples and is built with high-powered microscopes, computer vision, and artificial intelligence, providing accurate results in minutes with only two drops of blood. It is also the first CBC analyzer that is FDA 510(k) cleared for blood taken directly from either a
The two organizations have entered into an affiliation agreement under which Arcadia Trails INTEGRIS Health will leverage Hazelden Betty Ford s expertise to manage a 40-bed residential addiction treatment center
Center City, Minnesota, and Edmond, Oklahoma (April 9, 2021) Arcadia Trails INTEGRIS Health, a state-of-the-art addiction, mental health and trauma treatment center that is part of Oklahoma s largest health system, INTEGRIS Health, is joining forces with the Hazelden Betty Ford Foundation the nation s leading resource for individuals and families affected by substance use disorders to address the growing need for behavioral health services. The two organizations have entered into a three-year affiliation agreement under which Arcadia Trails INTEGRIS Health will leverage Hazelden Betty Ford s expertise through an agreement to manage the Arcadia Trails 40-bed residential treatment center in Edmond, Okla. Under the new agreement, Arcadia Trails becomes th